

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/629,114	07/29/2003	Harold Carrison	1001.1659101	6987	
28075 7.	590 08/11/2005		EXAMINER		
CROMPTON, SEAGER & TUFTE, LLC			MENDEZ, MANUEL A		
1221 NICOLLI SUITE 800	ET AVENUE		ART UNIT	PAPER NUMBER	
MINNEAPOLIS, MN 55403-2420			3763		

DATE MAILED: 08/11/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	on No.	Applicant(s)			
		10/629,11	4	CARRISON ET AL.			
	Office Action Summary	Examiner		Art Unit			
		Manuel Me		3763	_		
Period fo	The MAILING DATE of this communic or Reply	cation appears on the	cover sheet with the c	orrespondence address			
THE - Exte after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FO MAILING DATE OF THIS COMMUNIC nsions of time may be available under the provisions of SIX (6) MONTHS from the mailing date of this commus period for reply specified above is less than thirty (30) period for reply is specified above, the maximum stature to reply within the set or extended period for reply wreply received by the Office later than three months afted patent term adjustment. See 37 CFR 1.704(b).	CATION.  f 37 CFR 1.136(a). In no evenication.  days, a reply within the statutory period will apply and will lift by statute, cause the apple.	ent, however, may a reply be tim story minimum of thirty (30) days Il expire SIX (6) MONTHS from ication to become ABANDONEC	ely filed  will be considered timely. the mailing date of this communication.  (35 U.S.C. § 133).			
Status							
1)⊠	Responsive to communication(s) filed	I on <i>04/21/2005</i> .					
· —	•	b)⊠ This action is n	on-final.				
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims						
5)□ 6)⊠ 7)□	Claim(s) 1-64 is/are pending in the application.  4a) Of the above claim(s) 9-11,20 and 50-52 is/are withdrawn from consideration.  Claim(s) is/are allowed.  Claim(s) 1-8,12-19,21-24,41-49 and 53-64 is/are rejected.  Claim(s) is/are objected to.  Claim(s) are subject to restriction and/or election requirement.						
Applicat	ion Papers						
9)□	The specification is objected to by the	Examiner.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
	Applicant may not request that any object	ion to the drawing(s) b	e held in abeyance. See	37 CFR 1.85(a).			
11)	Replacement drawing sheet(s) including t The oath or declaration is objected to	•		·			
Priority (	under 35 U.S.C. § 119						
a)	Acknowledgment is made of a claim for All b) Some * c) None of:  1. Certified copies of the priority of Some * Copies of the priority of Some * Copies of the priority of Some * Copies of the certified copies of the certified copies of the certified copies of the certified copies of the attached detailed Office action	locuments have bee locuments have bee f the priority docume al Bureau (PCT Rule	n received. n received in Application ents have been receive e 17.2(a)).	on No Id in this National Stage			
Attachmen	ıt(s)						
1) Notic	ce of References Cited (PTO-892)		4) Interview Summary				
3) Infor	ce of Draftsperson's Patent Drawing Review (PT mation Disclosure Statement(s) (PTO-1449 or P er No(s)/Mail Date		Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	te atent Application (PTO-152)			

Art Unit: 3763

#### **DETAILED ACTION**

#### Election/Restrictions

Claims 9-11, 20, and 50-52 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on April 21, 2005.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000.

Art Unit: 3763

Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Kokish et al.

The cited patent discloses an apparatus that performs a method comprising providing an apparatus having a first deployable structure, and a second deployable structure, inserting the apparatus into a vessel adjacent the treatment site such that the first deployable structure is disposed adjacent the treatment site and the second deployable structure is disposed at a location proximal or distal of the treatment site, introducing a treatment material into the vessel proximate the treatment site, deploying the second deployable structure within the vessel, and deploying the first deployable structure adjacent the treatment site to create movement of the material adjacent the treatment site.

### Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 2-8, 12-19, 21-24, 41-49 and 53-64 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kokish et al., in view of Tsugita and Harrison, et al., and in further view of Wright, Slepian, Goodin, Bagaoisan et al.

The Kokish et al., patent does not disclose the use of a filter at the most distal end of the catheter and the infusion of drugs such as streptokinase. However, such

Art Unit: 3763

enhancements are conventional in the art as evidenced by the teachings Tsugita and Harrison, et al.

The Tsugita patent discloses the use of an expandable filter in combination with single and double balloon catheters to isolate the area of treatment. The Harrison, et al., patent demonstrates that infusing drugs such as streptokinase into the body for treatment of vessels is conventional in the art.

Based on the above observations, for a person of ordinary skill in the art, modifying the apparatus disclosed by Kokish et al., with the enhancements taught by Tsugita and Harrison, et al., would have been considered obvious in view of the conventionality of these enhancements.

The examiner of record has included the Wright, Slepian, Goodin, and Bagaoisan et al., patents to further demonstrate that the use of double and triple balloon catheter combinations to infuse drugs into isolated areas of a vessel is well known in the art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Manuel Mendez whose telephone number is 703-272-4977. The examiner can normally be reached on 0730-1800 hrs.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Nicholas D. Lucchesi can be reached on 571-272-4977. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/629,114

**Art Unit: 3763** 

Page 5

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free)

Manuel Mendez **Primary Examiner** 

Art Unit 3763

MM